Sulfopin, a selective covalent inhibitor of Pin1, blocks Myc-driven tumor initiation and growthin vivo

Author:

Dubiella Christian,Pinch Benika J.,Zaidman Daniel,Manz Theresa D.,Poon Evon,He Shuning,Resnick Efrat,Langer Ellen M.,Daniel Colin J.,Seo Hyuk-Soo,Chen Ying,Ficarro Scott B.,Jamin Yann,Lian Xiaolan,Kibe Shin,Kozono Shingo,Koikawa Kazuhiro,Doctor Zainab M.,Nabet Behnam,Browne Christopher M.,Yang Annan,Stoler-Barak Liat,Shah Richa B.,Vangos Nick E.,Geffken Ezekiel A.,Oren Roni,Sidi Samuel,Shulman Ziv,Wang Chu,Marto Jarrod A.,Dhe-Paganon Sirano,Look Thomas,Zhou Xiao Zhen,Lu Kun Ping,Sears Rosalie C.,Chesler Louis,Gray Nathanael S.,London Nir

Abstract

AbstractThe peptidyl-prolyl cis-trans isomerase, Pin1, acts as a unified signaling hub that is exploited in cancer to activate oncogenes and inactivate tumor suppressors, in particular through up-regulation of c-Myc target genes. However, despite considerable efforts, Pin1 has remained an elusive drug target. Here, we screened an electrophilic fragment library to discover covalent inhibitors targeting Pin1’s active site nucleophile - Cys113, leading to the development of Sulfopin, a double-digit nanomolar Pin1 inhibitor. Sulfopin is highly selective for Pin1, as validated by two independent chemoproteomics methods, achieves potent cellular andin vivotarget engagement, and phenocopies genetic knockout of Pin1. Although Pin1 inhibition had a modest effect on viability in cancer cell cultures, Sulfopin induced downregulation of c-Myc target genes and reduced tumor initiation and tumor progression in murine and zebrafish models of MYCN-driven neuroblastoma. Our results suggest that Sulfopin is a suitable chemical probe for assessing Pin1-dependent pharmacology in cells andin vivo. Moreover, these studies indicate that Pin1 should be further investigated as a potential cancer target.

Publisher

Cold Spring Harbor Laboratory

Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3